Clinical Trial

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-04-19; most recent amendment 2025-09-12.
Status change: Recruiting → Active, Not Recruiting 2025-09-12
Status change: Not Yet Recruiting → Recruiting 2024-08-05
Trial Details
NCT Number NCT06381141
Lead Sponsor Cullinan Therapeutics Inc.
Conditions Multiple Myeloma
Enrollment 30 participants
Start Date 2024-09-03
Primary Completion 2026-09 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-18